Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19
18 August 2022
| COVID-19: Vaccines
Overview
These are the annexes to WHO interim recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 vaccine against Covid-19. Annexes 1–6 contain tables that summarize the grading of recommendations, assessment, development and evaluations (GRADE). Annexes 7–9 contain the SAGE evidence-to-recommendation framework tables (ETR tables).
GRADE and ETR tables are updated as recommendations are updated.
This document has been updated: Version 18 August 2022.
Related documents:
Interim recommendations for use of the Pfizer–BioNTech BNT162b2 vaccine
Archived version:
- Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19. Version 21 January 2022.
- Annexes to the recommendations for use of the Pfizer–BioNTech vaccine BNT162b2 against COVID-19. Version 19 November 2021.
- Annexes to the recommendations for use of the BNT162b2 vaccine. Version 15 June 2021.
Editors
WHO
Number of pages
75
Reference numbers
WHO Reference Number: WHO-2019-nCoV-vaccines-SAGE-recommendation-BNT162b2-annexes-2022.1
Copyright
